KDM1A and breast carcinoma: To the best of our knowledge, this review is the first to comprehensively evaluate LSD1 inhibition effects on promising enhanced immunogenicity in breast cancer studies, alongside highlighting the limited clinical studies on LSD1-targeting therapies in breast cancer patients.